Clinical Trial: NCT03521154
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-08-04 |
Study Overview
Brief Summary
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Official Title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).
Conditions
Non Small Cell Lung Cancer (Stage III)
Intervention / Treatment
- Drug: Osimertinib 80mg/40mg
- Drug: Placebo Osimertinib 80mg/40mg
Other Study ID Numbers
- D5160C00048
- 2022-500860-36-00
- 2018-001061-16
- 2018
Start Date (Actual)
2018-07-19
Primary Completion Date (Actual)
2024-01-05
Study Completion Date (Estimated)
2027-10-29
Enrollment (Actual)
216
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-08-04 |
Study Overview
Brief Summary
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Official Title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).
Conditions
Non Small Cell Lung Cancer (Stage III)
Intervention / Treatment
- Drug: Osimertinib 80mg/40mg
- Drug: Placebo Osimertinib 80mg/40mg
Other Study ID Numbers
- D5160C00048
- 2022-500860-36-00
- 2018-001061-16
- 2018
Start Date (Actual)
2018-07-19
Primary Completion Date (Actual)
2024-01-05
Study Completion Date (Estimated)
2027-10-29
Enrollment (Actual)
216
Study Type
Interventional
Phase
Phase 3